Health Outcomes, Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI, USA.
Drug Saf. 2021 Dec;44(12):1297-1309. doi: 10.1007/s40264-021-01115-6. Epub 2021 Oct 5.
Prescription opioids are frequently used for pain management in pregnancy. Studies examining perinatal complications in mothers who received prescription opioids during pregnancy are still limited.
The aim of this study was to assess the association of prescription opioid use and maternal pregnancy and obstetric complications.
This retrospective cohort study with the Rhode Island (RI) Medicaid claims data linked to vital statistics throughout 2008-2015 included pregnant women aged 12-55 years with one or multiple live births. Women were excluded if they had cancer, opioid use disorder, or opioid dispensing prior to but not during pregnancy. Main outcomes included adverse pregnancy and obstetric complications. Marginal Structural Cox Models with time-varying exposure and covariates were applied to control for baseline and time-varying covariates. Analyses were conducted for outcomes that occurred 1 week after opioid exposure (primary) or within the same week as exposure (secondary). Sensitivity studies were conducted to assess the effects of different doses and individual opioids.
Of 9823 eligible mothers, 545 (5.5%) filled one or more prescription opioid during pregnancy. Compared with those unexposed, no significant risk was observed in primary analyses, while in secondary analyses opioid-exposed mothers were associated with an increased risk of cesarean antepartum depression (HR 3.19; 95% CI 1.22-8.33), and cardiac events (HR 9.44; 95% CI 1.19-74.83). In sensitivity analyses, results are more prominent in high dose exposure and are consistent for individual opioids.
Prescription opioid use during pregnancy is associated with an increased risk of maternal complications.
处方类阿片类药物常用于妊娠期间的疼痛管理。尽管已有研究探讨了孕期使用处方类阿片药物与围产期并发症之间的关系,但此类研究仍然有限。
本研究旨在评估孕期使用处方类阿片药物与产妇妊娠和产科并发症之间的关联。
这是一项回顾性队列研究,使用了 2008 年至 2015 年期间罗德岛(RI)医疗补助索赔数据,并与整个孕期的生命统计数据相链接,纳入了年龄在 12-55 岁之间、有一次或多次活产的孕妇。如果患者患有癌症、阿片类药物使用障碍或在妊娠前但不在妊娠期间使用阿片类药物,则将其排除在外。主要结局包括不良妊娠和产科并发症。采用时间变化的暴露和协变量的边缘结构 Cox 模型来控制基线和时间变化的协变量。对在阿片类药物暴露后 1 周(主要)或与暴露同时发生的(次要)的结局进行了分析。还进行了敏感性研究,以评估不同剂量和单一阿片类药物的影响。
在 9823 名符合条件的母亲中,有 545 名(5.5%)在妊娠期间开具了一种或多种处方类阿片药物。与未暴露组相比,在主要分析中未观察到显著风险,而在次要分析中,阿片类药物暴露的母亲发生剖宫产、产前抑郁的风险增加(HR 3.19;95%CI 1.22-8.33)和心脏事件(HR 9.44;95%CI 1.19-74.83)的风险增加。在敏感性分析中,高剂量暴露的结果更为显著,且对单一阿片类药物的结果一致。
孕期使用处方类阿片药物与产妇并发症风险增加相关。